Efficacy Analysis of Immunotherapy-based Combinations for EGFR-Mutant Advanced Non-Small Cell Lung Cancer Patients After TKI Failure

Treatment for EGFR-mutant advanced NSCLC after TKI failure are limited. Immunotherapy for this disease has been challenging. Our study showed reviewed the efficacy of patients with EGFR-mutant advanced NSCLC who were treated with PD-1 inhibitor-based combinations after TKI failure.